Spago Nanomedical Year-End Report January-December, 2025

About this update from Spago Nanomedical Ab

[{"type":"text","content":"LUND, SE / ACCESS Newswire / February 5, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)","length":91,"tagName":"p"},{"type":"text","content":"OCTOBER - DECEMBER IN BRIEF","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales for the quarter amounted to KSEK 4 (KSEK 617)","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"The loss for the quarter amounted to KSEK -5,890 (KSEK -7,830)","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating expenses for the quarter amounted to KSEK -6,943 (KSEK -10,223)","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"Earnings per share, before and after dilution, for the quarter amounted to SEK -0.01 (SEK -0. 02)","length":97,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":287,"olType":false},{"type":"text","content":"JANUARY - DECEMBER IN BRIEF","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales for the year amounted to KSEK 437 (KSEK 1,911)","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"The loss for the year amounted to KSEK -26,554 (KSEK -32,509)","length":61,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating expenses for the year amounted to KSEK -31,766 (KSEK -40,626)","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Earnings per share, before and after dilution, for the year amounted to SEK -0.07 (SEK -0. 11)","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents at the end of the year amounted to KSEK 29,672 (KSEK 32,470)","length":86,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":368,"olType":false},{"type":"text","content":"SIGNIFICANT EVENTS DURING THE QUARTER","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The independent Data Monitoring Committee (DMC) recommended a dose escalation in the ongoing phase I/IIa Tumorad-01 study with the drug candidate 177Lu-SN201 in radiotherapy. In addition, significant visible tumor uptake of 177Lu-SN201 has been observed in SPECT images. The DMC considers this observation to be proof-of-concept for Tumorad in humans, indicating that 177Lu-SN201 may be a potential new treatment for cancer. This provides strong support for continued development, as well as an important basis for exp...

More updates from Spago Nanomedical Ab